BACKGROUND Impaired functional capacity is a hallmark of patients with heart failure with preserved ejection fraction
H eart failure with preserved ejection fraction (HFpEF) is responsible for approximately 50% of prevalent heart failure (HF), and has a high morbidity and mortality (1, 2) . An increase in the prevalence of HFpEF is likely to continue with the aging of the population and high proportions of hypertension, diabetes, and obesity (2, 3) .
However, no specific treatment for this condition appears to be effective, which could be in part due to diagnostic challenges and the heterogeneity of the HFpEF phenotype (4-6). The latter is probably responsible for diverse results with novel therapeutic options for HFpEF: negative (7) or only partly positive (8) for spironolactone, negative for nitric oxide (9) and sildenafil (10) , and both positive (11) and negative (12) Although clinical trials of MRA in subjects with HFpEF have not shown prognostic benefit (7, 8) , these elderly patients may seek improved functional capacity and symptom status as much as longer survival. Given this, we postulated that an antifibrotic effect of spironolactone might reduce the increment in estimated LVFP, thus alleviating exercise intolerance, and that patients with abnormal diastolic response to exertion might be the appropriate target population for this therapy. Accordingly, the STRUCTURE (SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity) trial was designed to identify improvement in exercise capacity with spironolactone in HFpEF with an exercise-induced increase in the echo Doppler-derived ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e 0 ), reflecting LVFP. Written informed consent was provided by all subjects before involvement in the study. Heart rate reserve (reflecting the chronotropic response during exertion) was assessed as the change in heart rate from rest to peak exercise expressed as a percentage of the predicted heart rate reserve (i.e., the difference between the predicted maximal heart rate and the resting heart rate). 90% power to show a difference in exercise capacity at a 2-sided a of 0.05. To allow for dropouts, the number of patients in each arm was increased to 75.
All patients had complete data for the primary and secondary outcomes, although full gas exchangederived data at both baseline and follow-up were available in 120 patients (60 patients/arm). No imputation of the data was performed. Analyses for investigated variables, including the primary and secondary endpoints, followed the same analytic approach.
Between-group comparisons were carried out with an Tables 3 and 4 ).
BLOOD MARKERS. No significant alterations were noted at follow-up in circulating BNP and galectin-3 in both study arms (Online Table 1 ).
SUBGROUP ANALYSIS. Significant improvement with spironolactone (as compared with placebo) was found in subgroups above and below an RER of 1 (the achievement of which was used to define maximum effort), with the effect size being medium at RER >1 and large at RER <1. The effect of spironolactone on exercise E/e 0 showed a large effect size in both subgroups. In the group with RER <1 at baseline, spironolactone was associated with an increase in RER, which was not observed in patients treated with placebo ( Figure 2 ).
DETERMINANTS OF IMPROVEMENT IN EXERCISE
CAPACITY. A series of multivariable models adjusted for clinical and demographic covariates (Table 5) showed that improvement in exercise capacity was independently associated with change in exertional increase in E/e 0 and VAC from baseline to follow-up, as well as baseline galectin-3; however, low R 2 values of the models are indicative of a relatively poor model fit.
Treatment with spironolactone and change in exercise E/e 0 showed a significant interaction with respect to improvement in peak VO 2 (p ¼ 0.039). ADVERSE EVENTS. Adverse events during follow-up were rare (Online Table 2 ). Spironolactone was associated with a small increase in serum potassium (Online Table 1 ). In 2 patients experiencing hyperkalemia (>5.5 mmol/l), the study drug was temporarily discontinued, and after the adjustment of Values are mean (95% CI). The p value for treatment effect indicates the significance of interaction between treatment and time (baseline to 6 months). The primary endpoint was E/e 0 mean; the secondary endpoints were peak systolic BP and GLS. Tables 2 and 3. JACC VOL. 68, NO. 17, 2016
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Aldosterone Antagonism in HFpEF angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker dosing and decrease in serum potassium level, the treatment was reinstituted.
LOSS TO FOLLOW-UP. There were no significant differences in all patient characteristics presented in
Online Table 3 between the groups of enrollees with complete and incomplete follow-up.
REPRODUCIBILITY. The intraobserver and interobserver variability of echocardiographic measurements of imaging outcomes-E/e 0 ratio and GLS-were assessed in 15 randomly selected examinations, and were analyzed twice by 2 observers blinded to patient clinical data on 2 separate days with the time interval of 2 weeks (Online Table 4 ).
DISCUSSION
The STRUCTURE study demonstrated that the addition of spironolactone to existing therapy for 6 months in patients with HFpEF and abnormal diastolic response to exertion led to increased exercise capacity independent of changes in BP, and that improvement in LV diastolic filling at exercise (exercise E/e 0 ratio) might be a contributor to this beneficial effect (Central Illustration). D ¼ change from baseline to follow-up; CI ¼ confidence interval; HFpEF = heart failure with preserved ejection fraction; VO 2 ¼ oxygen uptake.
CENTRAL ILLUSTRATION
Kosmala et al. Treatment with spironolactone caused a significant reduction of BP at rest, leaving exertional BP unchanged; however, the improvement in exercise capacity was independent of this hypotensive effect.
In contrast to the post hoc analysis of the TOPCAT
(Treatment of Preserved Cardiac Function Heart
Failure with an Aldosterone Antagonist) data (33), spironolactone-induced improvement in GLS did not reach statistical significance in our HFpEF population.
However, the degree of post-treatment change was similar between both studies, and significant differences might be expected with a larger sample size. Variables included in the analysis in each model: Model 1: galectin-3 at baseline, age, sex, BMI, presence of diabetes, hypertension, treatment with beta blockers and ACE inhibitors, changes from baseline to follow-up in exertional increase in E/e 0 , VAC and GLS, blood pressure and its changes during follow-up, creatinine, LVMI, LA strain, EF, CO, SVR, and their changes during follow-up. Model 2: galectin-3 at baseline, age, sex, BMI, presence of diabetes, hypertension, treatment with beta blockers and ACE inhibitors, changes from baseline to follow-up in exertional increase in E/e 0 , blood pressure and its changes during follow-up, creatinine, LVMI, LA strain, EF, CO, SVR, and their changes during follow-up. Model 3: galectin-3 at baseline, age, sex, BMI, presence of diabetes, hypertension, treatment with beta blockers and ACE inhibitors, changes from baseline to follow-up in exertional increase in VAC, blood pressure and its changes during follow-up, creatinine, LVMI, LA strain, EF, CO, SVR, and their changes during follow-up. Model 4: galectin-3 at baseline, age, sex, BMI, presence of diabetes, hypertension, treatment with beta blockers and ACE inhibitors, changes from baseline to follow-up in exertional increase in GLS, blood pressure and its changes during follow-up, creatinine, LVMI, LA strain, EF, CO, SVR, and their changes during follow-up.
ACE ¼ angiotensin-converting enzyme; BL ¼ baseline; EF ¼ ejection fraction; FU ¼ follow-up; LVMI ¼ left ventricular mass index; other abbreviations as in Tables 1 and 2 . Aldosterone Antagonism in HFpEF
